Abstract
Broad-spectrum reactivator is an oxime which is able to reactivate acetylcholinesterase (AChE) inhibited by many kinds of organophosphate inhibitors of AChE, mainly nerve agents. There are many AChE reactivators (oximes) as suitable candidates for the broad-spectrum reactivator. Among them, oxime HI-6 is considered as number one, and due to its properties, it is recommended by many armies to be introduced as universal antidotal mean. In this study, we wanted to summarize that the designation “broad spectrum” is prerogative. For this purpose, in vivo evaluation of therapeutical dose of HI-6 (39.0 mg/kg) was performed. Soman, cyclosarin and tabun were used as the typical members of nerve agent family. According to the obtained results, oxime HI-6 did not sufficiently reactivate tabun-inhibited AChE. Brain AChE was also only partially protected. Based on these results, it seems that HI-6 in therapeutical dose has effect only in peripheral compartment.
Keywords: HI-6, Tabun, Cyclosarin, Soman, Broad-spectrum, Oxime
Letters in Drug Design & Discovery
Title: Potency of HI-6 to Reactivate Cyclosarin, Soman and Tabun Inhibited Acetylcholinesterase – In Vivo Study
Volume: 7 Issue: 7
Author(s): Jana Zdarova Karasova, Jiri Kassa, Miroslav Pohanka, Kamil Musilek and Kamil Kuca
Affiliation:
Keywords: HI-6, Tabun, Cyclosarin, Soman, Broad-spectrum, Oxime
Abstract: Broad-spectrum reactivator is an oxime which is able to reactivate acetylcholinesterase (AChE) inhibited by many kinds of organophosphate inhibitors of AChE, mainly nerve agents. There are many AChE reactivators (oximes) as suitable candidates for the broad-spectrum reactivator. Among them, oxime HI-6 is considered as number one, and due to its properties, it is recommended by many armies to be introduced as universal antidotal mean. In this study, we wanted to summarize that the designation “broad spectrum” is prerogative. For this purpose, in vivo evaluation of therapeutical dose of HI-6 (39.0 mg/kg) was performed. Soman, cyclosarin and tabun were used as the typical members of nerve agent family. According to the obtained results, oxime HI-6 did not sufficiently reactivate tabun-inhibited AChE. Brain AChE was also only partially protected. Based on these results, it seems that HI-6 in therapeutical dose has effect only in peripheral compartment.
Export Options
About this article
Cite this article as:
Zdarova Karasova Jana, Kassa Jiri, Pohanka Miroslav, Musilek Kamil and Kuca Kamil, Potency of HI-6 to Reactivate Cyclosarin, Soman and Tabun Inhibited Acetylcholinesterase – In Vivo Study, Letters in Drug Design & Discovery 2010; 7 (7) . https://dx.doi.org/10.2174/157018010791526269
DOI https://dx.doi.org/10.2174/157018010791526269 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Anesthesia, Calcium Homeostasis and Alzheimers Disease
Current Alzheimer Research MYC-mediated Synthetic Lethality for Treatment of Hematological Malignancies
Current Cancer Drug Targets Identifying the Predictors of Self-Management Behaviors in Patients with Diabetes Based on Ecological Approach: A Systematic Review
Current Diabetes Reviews Imaging β-Amyloid Plaques and Neurofibrillary Tangles in the Aging Human Brain
Current Pharmaceutical Design Protein Kinases and their Modulation in the Central Nervous System
Current Medicinal Chemistry - Central Nervous System Agents Effects of 8-Residue Beta Sheet Breaker Peptides on Aged Aβ40 – Induced Memory Impairment and Aβ40 Expression in Rat Brain and Serum Following Intraamygdaloid Injection
Current Alzheimer Research The Cold Case of Metabotropic Glutamate Receptor 6: Unjust Detention in the Retina?
Current Neuropharmacology PAI-1 Antagonists: Predictable Indications and Unconventional Applications
Current Drug Targets Amyloid Beta (Aβ) Protein- and Amyloid Precursor Protein (APP)- Immunoreactive Structures in the Brains of Aged Tree Shrews
Current Aging Science Polycystic Ovary Syndrome in Adolescents
Current Women`s Health Reviews Differential Influences of Gastric Bypass and Sleeve Gastrectomy on Plasma Nesfatin-1 and Obestatin Levels in Patients with Type 2 Diabetes Mellitus
Current Pharmaceutical Design Prospective Role of Polyphenolic Compounds in the Treatment of Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets Drugs from the Sea: Conopeptides as Potential Therapeutics
Current Medicinal Chemistry RNAi-based Gene Therapy for Dominant Limb Girdle Muscular Dystrophies
Current Gene Therapy Heterocyclic Curcumin Derivatives of Pharmacological Interest: Recent Progress
Current Topics in Medicinal Chemistry Inhibition of NF-kB Activation and Cytokines Production in THP-1 Monocytes by 2-Styrylchromones
Medicinal Chemistry Beta Blockers and Chronic Obstructive Pulmonary Disease (COPD): Sum of Evidence
Current Hypertension Reviews Mechanisms of Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Advanced Non-Small-Cell Lung Cancer: Clinical and Molecular Considerations
Current Medicinal Chemistry Crude Venom from Nematocysts of the Jellyfish Pelagia noctiluca as a Tool to Study Cell Physiology
Central Nervous System Agents in Medicinal Chemistry Pyruvate Dehydrogenase Kinases in the Nervous System: Their Principal Functions in Neuronal-glial Metabolic Interaction and Neuro-metabolic Disorders
Current Neuropharmacology